Zhong Li

FDA investigator

Appears on 25 documents from 2016 to 2026, most often at sites in India. Most often cites control of microbiological contamination (21 CFR 211.113).

25
Documents on file
5.8
Observations per 483
2016
First seen
2026
Most recent

What they cite most

From 141 observations

Activity by year

2016: 1, 2017: 3, 2018: 1, 2019: 2, 2020: 2, 2021: 1, 2022: 5, 2023: 3, 2024: 4, 2025: 2, 2026: 1

Where

India 4 · Austria 2 · Ireland 2 · Japan 2 · South Korea 2 · California 1

Is Zhong Li coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

25 documents, newest first
FirmOpen
483 Bora PharmaceuticalsMar 20, 2026 · Baltimore, Maryland
483 Alvotech HfJul 4, 2025 · Reykjavik, Iceland
483 Fujifil m Diosyn th Biotechnologies Texas, LLCMar 11, 2025 · College Station, Texas
483 TERUMO CORPORATIONDec 13, 2024 · SHOWACHO, Japan
483 GlaxoSmithKline LLCSep 25, 2024 · Conshohocken, Pennsylvania
483 Patheon Manufacturing Services LLCMay 24, 2024 · Greenville, North Carolina
483 Amgen, IncFeb 6, 2024 · Thousand Oaks, California

About this profile

What does Zhong Li inspect?

Zhong Li appears on 25 documents on file covering 23 sites, most often in India.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.68 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Zhong Li is dated Mar 20, 2026.

FDA Investigator Zhong Li: 483s & Inspections · FDA Intel